Default company panoramic image
Logo 20 200x200px

ImStar Therapeutics

ImStar is developing a breakthrough new therapeutics for Amyotrophic Lateral Sclerosis (ALS)

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, BC, Canada
  • Currency CAD
  • Founded September 2012
  • Employees 10
  • Incorporation Type C-corp
  • Website imstartx.com

Company Summary

At ImStar Therapeutics, we are developing a breakthrough new approach to treat patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. By exploiting a major new biological target behind the underlying the disease, we expect to make great strides in treating this devastating neurological condition and other related neurodegenerative disorders such as Dementia, Alzheimer's Disease and Parkinson's Disease.

Team

  • Default avatar
    Daniel Wattier
    Chief Executive Officer

    Dan co-founder / CEO of Valocor Therapeutics. Led company until its acquisition by Dermira in 2011. Prior to Valocor, Dan was VP Commercial at QLT and served as President of its QLT Specialty Medicine division. Dan previously held senior positions in several pharma/biotech companies including Schering-Plough and Johnson & Johnson, where he was responsible for the US launch of Remicade, achieving over $8B in annual sales worldwide.

  • Default avatar
    Jean-Pierre Julien, PhD
    Chief Scientific Officer

    Dr. Julien is a world leader in ALS and neurodegenerative disease. He has published over 160 peer-reviewed papers, many in top ranked journals such as: Cell, Neuron, Science, Nature, among others. He is a member of the Robert Packard Center for ALS at Johns Hopkins University, the Gairdner Medical Review Panel, the ALS Society of Canada and is a recipient of the prestigious Sheila Essey Award for research from the American Academy of Neurology.

  • Default avatar
    Julia Levy, PhD
    Chairman

    Dr. Levy was co-founder of QLT and had served as its CEO and CSO. She has been the recipient of many awards for her achievements in business and science including: the Order of Canada, the Female Entrepreneur of the Year, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. She has also served as a Director of numerous biotechnology companies including AnoMED, Aspreva, Cynapsus, Twinstrand, Valocor and Vida.

Advisors

  • Default avatar
    James Hatton
    Lawyer
    Unconfirmed
    Default avatar
    Bashir Jaffer CA/CPA
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Founders
    Unconfirmed
    Default avatar
    Friends & Family
    Unconfirmed